

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Supporting Information

Metal-free synthesis of dihydrofuran derivatives as anti-vicinal amino alcohol isosteric equivalents

Bhargav Gupta Nangunuri^a, Rajendra P. Shirke^a and Mi-hyun Kim^{a,*}

^aGachon Institute of Pharmaceutical Science and Department of Pharmacy, College of Pharmacy, Gachon University, 191 Hambakmoeiro, Yeonsu-gu, Incheon, Republic of Korea

Content	Pages
1. General Information	2
2. Experimental section: General procedures and characterization data	3 - 25
3. Copies of ¹ H and ¹³ C NMR spectra for substrates and products	26 - 67
4. MTT Assay results	68 - 70
5. References and Notes	71

25 **EXPERIMENTAL SECTION**

26 **1. General Information**

27 All purchased reactants and reagents were used without further purification. BRUKER NMR
28 instruments used for ^1H NMR (600 MHz) and ^{13}C NMR (150 MHz) spectra were recorded in CDCl_3 with
29 regard to tetramethylsilane (TMS) as a reference for chemical shift values. Chemical shifts (δ) were
30 described in parts per million (ppm) and coupling constants (J) are referenced in hertz (Hz). Data are
31 reported as follows: chemical shift [multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m =
32 multiplet, br = broad)]. Organic solvents were concentrated on EYELA SB-1200. Rotary evaporator and
33 vacuum pump EYELA CCA-1111. Silica gel (60-120 mesh) was used for the purification of crude
34 products by column chromatography. Thin-layer chromatography (TLC) was presented on precoated silica
35 gel 60 F254 MERCK and visualized by exposing UV light. Melting points were recorded on OptiMelt
36 automatic melting point system.

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51 2. Experimental section: General procedures and characterization data

52 2.1. Synthesis of hypervalent iodine reagent

53 Acetoxy((4-methyl)-N-tosylbenzenesulfonamidyl)iodosobenzene (**1a**):



55 Synthesized according to the reported literature ¹.

56 To a solution of Iodobenzene diacetate (1.0 g, 3.1 mmol) in CH₂Cl₂ (20 mL) was added 4-methyl-
57 N-tosylbenzenesulfonamide (1.0 g, 3.1 mmol) and the reaction mixture stirred at room temperature during
58 0.5 h. The solvent was removed under the reduced pressure obtaining the title compound **1a** as a white
59 solid in quantitative yield.

60 Analytical data is in accordance with the literature ¹.

61 ¹H NMR (600 MHz, DMSO-d₆) δ 8.22 (dd, *J* = 8.3, 1.0 Hz, 2H), 7.70 (t, *J* = 1.1 Hz, 1H), 7.65 – 7.58 (m,
62 2H), 7.52 (d, *J* = 8.2 Hz, 4H), 7.15 (d, *J* = 7.9 Hz, 4H), 2.32 (s, 6H), 1.91 (s, 3H).

63 ¹³C NMR (151 MHz, DMSO-d₆) δ 172.49, 144.02, 140.21, 135.01, 132.97, 131.68, 128.71, 126.65,
64 123.91, 21.53, 21.32.

65

66

67

68

69


70

71

72

73

74

75 **2.2. General procedure for the synthesis of starting materials (8a-l)**


76

77 **General Procedure for the synthesis of 7a-l:**

78 To a stirred solution of ketone/aldehyde (1.0 mmol) in MeOH (2 mL) was added NaBH₄ (37 mg,
79 1.0 mmol) in single portion. The reaction mixture was stirred until full consumption of the starting
80 material (TLC analysis). The solvent was removed under reduced pressure and diluted the reaction
81 mixture with ice water (5 mL) and extracted into ether (3*10 mL). Combined extracts were washed with
82 brine (1*10 mL), dried over Na₂SO₄ and evaporated under reduced pressure. The residue was used
83 without any further purification.


84 * Compound **7a**, **7e**, **7j**, **7k** and **7l** were commercially available and used without further purification.

85 **1-phenylethanol (7b):**

86  Isolated as colorless oil; 98% Yield (119 mg). ¹H NMR (600 MHz, CDCl₃) δ 7.40 – 7.33
87 (m, 4H), 7.31 – 7.26 (m, 1H), 4.88 (d, *J* = 15.2 Hz, 1H), 2.51 (s, 1H), 1.60 – 1.39 (m, 3). ¹³C
88 NMR (151 MHz, CDCl₃) δ 145.90, 145.84, 128.50, 127.49, 127.45, 125.45, 125.41, 70.42,
89 70.33, 25.17.


90 Analytical data is in accordance with the literature ².

91 **Diphenylmethanol (7c):**

92  Isolated as white solid; 98% Yield (180 mg). ¹H NMR (600 MHz, CDCl₃) δ 7.40 (d, *J*
93 = 7.6 Hz, 4H), 7.35 (t, *J* = 7.4 Hz, 4H), 7.32 – 7.25 (m, 2H), 5.85 (s, 1H), 2.36 – 2.23
94 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 143.82, 128.53, 127.61, 126.57, 76.29.


95 Analytical data is in accordance with the literature ³.

96 **1,2,3,4-tetrahydronaphthalen-1-ol (7d):**

97  Isolated as colorless liquid; 98% Yield (145 mg). ¹H NMR (600 MHz, CDCl₃) δ 7.43 (dd, *J*
98 = 6.2, 2.8 Hz, 1H), 7.23 – 7.17 (dd, 2H), 7.14 – 7.08 (m, 1H), 4.78 (t, 1H), 2.88 – 2.69 (m,
99 2H), 2.03 – 1.94 (m, 2H), 1.94 – 1.88 (m, 1H), 1.78 (ddd, *J* = 12.6, 6.4, 3.4 Hz, 1H), 1.70 (s,
100 1H). ¹³C NMR (151 MHz, CDCl₃) δ 138.81, 137.14, 129.04, 128.67, 127.61, 126.21, 68.18, 32.29, 29.26,
101 18.80.


102 Analytical data is in accordance with the literature ⁴.

103 **Cyclohex-2-enol (7f):**

104  Isolated as colorless oil; 92% Yield (90 mg). ¹H NMR (600 MHz, CDCl₃) δ 1.54-1.64 (m, 2H),
 105 1.69-1.74 (m, 1H), 1.84-1.89 (m, 1H), 1.93-1.95 (m, 1H), 1.99-2.04 (m, 1H), 4.16-4.21 (m, 1H),
 106 5.74 (dq, *J* 10.0, 2.4 Hz, 1H), 5.83 (dtd, *J* 10.2, 3.7, 1.3 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ
 107 18.92, 25.04, 32.02, 65.51, 129.82, 130.60.


108 Analytical data is in accordance with the literature ⁵.

109 **Chroman-4-ol (7g):**

110  Isolated as white solid; 95% Yield (142 mg). ¹H NMR (600 MHz, CDCl₃) δ 7.30 (dd, *J* =
 111 7.6, 1.6 Hz, 1H), 7.24 – 7.18 (m, 1H), 6.92 (td, *J* = 7.5, 1.1 Hz, 1H), 6.84 (dd, *J* = 8.3, 0.9
 112 Hz, 1H), 4.76 (s, 1H), 4.29 – 4.22 (m, 2H), 2.16 (s, 1H), 2.14 – 2.07 (m, 1H), 2.04 – 1.97
 113 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 154.58, 129.72, 129.71, 124.33, 120.60, 117.08, 63.21, 61.94,
 114 30.82.


115 Analytical data is in accordance with the literature ⁶.

116 **2,3-dihydro-1H-inden-1-ol (7h):**

117  Isolated as colorless oil; 90% Yield (120 mg). ¹H NMR (600 MHz, CDCl₃) δ 7.42 (d, *J*
 118 = 6.9 Hz, 1H), 7.30 – 7.20 (m, 3H), 5.23 (s, 1H), 3.06 (ddd, *J* = 15.9, 8.5, 4.8 Hz, 5H),
 119 2.86 – 2.76 (m, 1H), 2.48 (dddd, *J* = 13.1, 8.3, 6.9, 4.8 Hz, 1H), 2.18 (d, *J* = 9.8 Hz, 1H),
 120 1.94 (dddd, *J* = 13.7, 8.5, 6.6, 5.4 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 145.01, 143.34, 128.32,
 121 126.71, 124.91, 124.24, 76.40, 35.89, 29.81.

122 Analytical data is in accordance with the literature ⁴.

123 **6-(trifluoromethyl)-2,3-dihydro-1H-inden-1-ol (7i):**


124  Isolated as colorless oil; 80% Yield (161 mg). ¹H NMR (600 MHz, CDCl₃) δ 7.61 (s,
 125 1H), 7.48 (d, *J* = 7.9 Hz, 1H), 7.30 (d, *J* = 7.9 Hz, 1H), 5.16 (t, *J* = 6.3 Hz, 1H), 3.47
 126 (dd, *J* = 14.1, 7.0 Hz, 1H), 3.02 (ddd, *J* = 16.2, 8.6, 4.4 Hz, 1H), 2.85 – 2.75 (m, 1H),
 127 2.45 (dddd, *J* = 12.9, 8.3, 7.0, 4.5 Hz, 1H), 1.90 (dddd, *J* = 13.1, 8.6, 7.2, 5.8 Hz, 1H). ¹³C NMR (151
 128 MHz, CDCl₃) δ 147.36, 145.69, 129.11 (q, *J* = 32.0 Hz), 125.2 (q, *J* = 3.7 Hz), 125.17, 124.40, 121.25 (q,
 129 *J* = 3.8 Hz), 75.55, 35.71, 29.67.

130 Analytical data is in accordance with the literature ⁷.

131 **General Procedure for the synthesis of 8a-l:**


132 To a stirred solution of **7a-l** (1.0 mmol) in DMF (2mL) at 0°C was added NaH (28.8 mg, 1.2
 133 mmol) in a single portion. The reaction mixture was stirred for 30 minutes at the same temperature.
 134 Propargyl bromide (1.2 mmol) was added slowly to the above reaction mixture. Stirred until the full
 135 completion of starting material (TLC analysis). Reaction quenched with sat. NH₄Cl and extracted into
 136 ethyl acetate (3*10 mL). Combined extracts were washed with brine (1*10 mL), dried over Na₂SO₄ and
 137 evaporated under reduced pressure. The desired compound was obtained after purification by column
 138 chromatography (Hexane: EtOAc = 99:1 to 80:20).

139 **((prop-2-yn-1-yloxy)methyl)benzene (8a):**

140  Column Chromatography (Hexane: EtOAc = 9:1); Isolated as colorless liquid; 80%
 141 yield (118 mg). ¹H NMR (600 MHz, CDCl₃) δ 7.50 – 7.28 (m, 5H), 4.73 – 4.58
 142 (m, 2H), 4.28 – 4.14 (m, 2H), 2.53 (dd, *J* = 2.1, 1.4 Hz, 1H). ¹³C NMR (151 MHz,
 143 CDCl₃) δ 137.39, 128.54, 128.19, 127.99, 79.78, 74.78, 71.57, 57.13.


144 Analytical data is in accordance with the literature ⁸.

145 **(1-(prop-2-yn-1-yloxy)ethyl)benzene (8b):**


146  Column Chromatography (Hexane: EtOAc = 9:1); Isolated as colorless liquid; 85%
 147 yield (136 mg). ¹H NMR (600 MHz, CDCl₃) δ 7.38-7.31 (m, 5 H), 4.68 (q, *J* = 6.5
 148 Hz, 1 H), 4.10 (dd, *J* = 2.4, 15.7 Hz, 1 H), 3.90 (dd, *J* = 2.4, 15.7 Hz, 1 H), 2.43 (t, *J* =
 149 2.4 Hz, 1 H), 1.50 (d, *J* = 6.5 Hz, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 142.62,
 150 128.70, 128.01, 126.63, 80.21, 76.84, 74.26, 55.73, 23.90.

151 Analytical data is in accordance with the literature ⁹.

152 **((prop-2-yn-1-yloxy)methylene)dibenzene (8c):**

153  Column Chromatography (Hexane: EtOAc = 9:1); Isolated as colorless liquid; 65%
 154 yield (145 mg). ¹H NMR (600 MHz, CDCl₃) δ 7.50 (dd, *J* = 8.4, 1.3 Hz, 4H), 7.47 –
 155 7.41 (m, 4H), 7.40 – 7.34 (m, 2H), 5.81 (s, 1H), 4.27 (d, *J* = 2.5 Hz, 2H), 2.56 (t, *J* =
 156 2.4 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 141.42, 128.65, 127.89, 127.48, 81.81, 79.97, 74.95, 55.94.


157 Analytical data is in accordance with the literature ¹⁰.

158 **1-(prop-2-yn-1-yloxy)-1,2,3,4-tetrahydronaphthalene (8d):**

159 Column Chromatography (Hexane: EtOAc = 95:5); Isolated as colorless liquid; 65% yield (145 mg). ¹H
 160 NMR (600 MHz, CDCl₃) δ 7.50 (dd, *J* = 8.4, 1.3 Hz, 4H), 7.47 – 7.41 (m, 4H), 7.40 – 7.34 (m, 2H), 5.81
 161 (s, 1H), 4.27 (d, *J* = 2.5 Hz, 2H), 2.56 (t, *J* = 2.4 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 141.42, 128.65,
 162 127.89, 127.48, 81.81, 79.97, 74.95, 55.94.


163 HRMS (EI⁺ mode): Calculated for C₁₃H₁₄O: 186.1045, found: 186.1045.

164 **(prop-2-yn-1-yloxy)cyclohexane (8e):**

165  Column Chromatography (Hexane: EtOAc = 99:1); Isolated as colorless liquid; 85% yield
 166 (117 mg). ¹H NMR (600 MHz, CDCl₃) δ 4.17 (d, *J* = 2.3 Hz, 2H), 3.49-3.46 (m, 1H), 2.39
 167 (t, *J* = 2.3 Hz, 1H), 1.93-1.91 (m, 2H), 1.74-1.73 (m, 2H), 1.55-1.53 (m, 1H), 1.33-1.19 (m,
 168 5H); ¹³C NMR (151 MHz, CDCl₃) δ 80.6, 73.6, 54.9, 31.8, 25.7, 24.0.


169 Analytical data is in accordance with the literature ⁹.

170 **3-(prop-2-yn-1-yloxy)cyclohex-1-ene (8f):**

171  Column Chromatography (Hexane: EtOAc = 99:1); Isolated as colorless liquid; 55% yield
 172 (76 mg). ¹H NMR (600 MHz, CDCl₃) δ 5.83-5.87 (m, 1H), 5.74-5.77 (m, 1H), 4.16-4.18 (m,
 173 2H), 4.05-4.06 (m, 1H), 2.37-2.39 (m, 1H), 2.00-2.02 (m, 1H), 1.94-1.96 (m, 1H), 1.77-1.81
 174 (m, 1H), 1.66-1.74 (m, 2H), 1.52-1.55 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 131.20, 126.95, 73.58,
 175 71.34, 54.82, 24.71, 18.55.


176 Analytical data is in accordance with the literature ¹¹.

177 **4-(prop-2-yn-1-yloxy)chroman (8g):**

178  Column Chromatography (Hexane: EtOAc = 8:2); Isolated as colorless liquid; 70%
 179 yield (131 mg). ¹H NMR (600 MHz, CDCl₃) δ 7.30 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.25 –
 180 7.20 (m, 1H), 6.91 (td, *J* = 7.4, 1.1 Hz, 1H), 6.85 (dd, *J* = 8.3, 1.0 Hz, 1H), 4.69 (t, *J* =
 181 3.4 Hz, 1H), 4.35 – 4.18 (m, 4H), 2.51 (s, 1H), 2.19 – 2.03 (m, 2H). ¹³C NMR (151
 182 MHz, CDCl₃) δ 155.00, 130.85, 129.96, 120.64, 119.96, 117.10, 80.14, 74.70, 68.46, 61.96, 54.96, 27.54.

183 HRMS (EI⁺ mode): Calculated for C₁₂H₁₂O₂: 188.0837, found: 188.0835.


184 **1-(prop-2-yn-1-yloxy)-2,3-dihydro-1H-indene (8h):**

185  Column Chromatography (Hexane: EtOAc = 95:5); Isolated as colorless liquid; 90%
 186 yield (155 mg). ¹H NMR (600 MHz, CDCl₃) δ 7.45 (d, *J* = 7.4 Hz, 1H), 7.30 – 7.20
 187 (m, 3H), 5.17 (dd, *J* = 6.5, 3.6 Hz, 1H), 4.24 (d, *J* = 2.4 Hz, 2H), 3.17 – 3.07 (m, 1H),
 188 2.84 (ddd, *J* = 15.8, 8.5, 4.7 Hz, 1H), 2.48 (t, *J* = 2.4 Hz, 1H), 2.38 (ddt, *J* = 13.2, 8.5, 6.5 Hz, 1H), 2.16

189 (dddd, $J = 13.1, 8.3, 4.6, 3.7$ Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 144.34, 141.94, 128.63, 126.32,
 190 125.29, 125.01, 81.99, 80.29, 74.26, 55.69, 32.37, 30.25.


191 HRMS (EI⁺ mode): Calculated for $\text{C}_{12}\text{H}_{12}\text{O}$: 172.0888, found: 172.0886.

192 **1-(prop-2-yn-1-yloxy)-6-(trifluoromethyl)-2,3-dihydro-1H-indene (8i):**

193  Column Chromatography (Hexane: EtOAc = 9:1); Isolated as pale yellow
 194 liquid; 40% yield (96 mg). ^1H NMR (600 MHz, CDCl_3) δ 7.69 (s, 1H), 7.52
 195 (d, $J = 7.9$ Hz, 1H), 7.35 (d, $J = 7.9$ Hz, 1H), 5.21 – 5.12 (m, 1H), 4.31 – 4.20
 196 (m, 2H), 3.18 – 3.06 (m, 1H), 2.92 – 2.78 (m, 1H), 2.51 (d, $J = 1.9$ Hz, 1H), 2.46 – 2.37 (m, 1H), 2.17 (tdd,
 197 $J = 8.4, 4.9, 3.6$ Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 148.18, 143.07, 128.95 (q, $J = 32.0$ Hz), 125.63
 198 (q, $J = 3.7$ Hz), 123.55, 122.16 (q, $J = 3.8$ Hz), 81.47, 79.85, 74.68, 56.15, 32.36, 30.13.


199 HRMS (EI⁺ mode): Calculated for $\text{C}_{13}\text{H}_{11}\text{F}_3\text{O}$: 240.0762, found: 240.0761.

200 **5-((prop-2-yn-1-yloxy)methyl)benzo[d][1,3]dioxole (8j):**

201  Column Chromatography (Hexane: EtOAc = 8:2); Isolated as colorless liquid; 50%
 202 yield (95 mg). ^1H NMR (600 MHz, CDCl_3) δ 6.86 (d, $J = 1.6$ Hz, 1H), 6.81 (dd, $J =$
 203 7.9, 1.6 Hz, 1H), 6.77 (d, $J = 7.9$ Hz, 1H), 5.93 (s, 2H), 4.49 (s, 2H), 4.13 (d, $J = 2.5$
 204 Hz, 2H), 2.48 (t, $J = 2.4$ Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 147.81, 147.37, 131.10, 121.87, 108.83,
 205 108.09, 101.06, 79.75, 74.74, 71.30, 56.70.


206 Analytical data is in accordance with the literature ¹².

207 **2-methyl-5-(prop-2-yn-1-yloxy)hexane (8k):**

208  Column Chromatography (Hexane: EtOAc = 99:1); Isolated as pale yellow liquid;
 209 40% yield (61 mg). ^1H NMR (600 MHz, CDCl_3) δ 4.15 (qd, $J = 15.8, 2.4$ Hz, 2H),
 210 3.59 (h, $J = 6.1$ Hz, 1H), 2.38 (t, $J = 2.4$ Hz, 1H), 1.56 – 1.52 (m, 2H), 1.44 – 1.39
 211 (m, 2H), 1.18 (dd, $J = 4.3, 2.6$ Hz, 1H), 1.15 (d, $J = 6.1$ Hz, 3H), 0.89 (d, $J = 2.1$ Hz, 6H). ^{13}C NMR (151
 212 MHz, CDCl_3) δ 80.57, 74.99, 73.50, 55.48, 34.47, 34.20, 31.61, 28.13, 22.62, 19.27.

213 HRMS: (EI⁺ mode): Calculated for $\text{C}_{10}\text{H}_{18}\text{O}$: 154.1358, found: 154.1356.


214 **2-(prop-2-yn-1-yloxy)octane (8l):**

215  Column Chromatography (Hexane: EtOAc = 99:1); Isolated as pale yellow
 216 liquid; 50% yield (84 mg). ^1H NMR (600 MHz, CDCl_3) δ 4.15 – 4.09 (m,
 217 2H), 3.61 – 3.54 (m, 1H), 2.36 (t, $J = 2.4$ Hz, 1H), 1.52 (dt, $J = 15.8, 6.0$ Hz,
 218 1H), 1.36 (dt, $J = 9.7, 6.2$ Hz, 2H), 1.29 (d, $J = 6.9$ Hz, 2H), 1.27 – 1.24 (m, 4H), 1.23 (t, $J = 7.2$ Hz, 2H),

219 1.12 (d, $J = 6.2$ Hz, 3H), 0.86 (t, $J = 6.9$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 80.54, 74.63, 73.47,
 220 55.42, 36.37, 31.81, 29.34, 25.32, 22.60, 19.21, 14.05.

221 HRMS: (EI^+ mode): Calculated for $\text{C}_{11}\text{H}_{20}\text{O}$: 168.1514, found: 168.1511.


222 **2.3. General synthetic procedure for isatin substituents (3a-f):**



223


224 To a solution of **2** (1.0 mmol, 1.0 equiv.) in DMF (3 mL) was added NaH (1.5 mmol, 1.5 equiv.)
 225 at 0°C and stirred for 30 minutes, **R** substituted halogenated hydrocarbon (1.5 mmol, 1.5 equiv.) was
 226 added slowly and the reaction mixture was stirred at 0°C until the starting material was completely
 227 consumed. The reaction was quenched with saturated NH_4Cl and extracted with ethyl acetate (3*20 mL).
 228 Combined organic phase washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated
 229 under reduced pressure. The crude product was purified by flash column chromatography (Hexane: Ethyl
 230 Acetate = 9:1 – 1:1).

231 **1-methylindoline-2,3-dione (2a):**

232  Isolated as red color solid; 98% yield (157 mg). ^1H NMR (600 MHz, CDCl_3) δ 7.60-
 233 7.54 (m, 1H), 7.53-7.28 (m, 1H), 7.08 (t, $J = 7.5$ Hz, 1H), 6.87 (d, $J = 7.9$ Hz, 1H), 3.20
 234 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 144.34, 141.94, 128.63, 126.32, 125.29, 125.01,
 235 81.99, 80.29, 74.26, 55.69, 32.37, 30.25.


236 Analytical data is in accordance with the literature ¹³.

237 **1-ethylindoline-2,3-dione (2b):**

238  Isolated as red color solid; 69% yield (121 mg). ^1H NMR (600 MHz, CDCl_3) δ 7.63-
 239 7.57 (m, 2H), 7.12 (t, $J = 7.2$ Hz, 1H), 6.92 (d, $J = 7.6$ Hz, 1H), 3.80 (q, $J = 6.8$ Hz, 2H),
 240 1.32 (t, $J = 6.8$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 183.7, 157.9, 150.7, 138.4,
 241 125.5, 123.7, 117.7, 110.1, 35.0, 12.6.


242 Analytical data is in accordance with the literature ¹³.

243 **1-isopropylindoline-2,3-dione (2c):**

244  Isolated as red color solid; 85% yield (160 mg). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.60-
 245 7.53 (m, 2H), 7.09-7.01 (m, 2H), 4.55-4.48 (m, 1H), 1.51 (d, $J = 6.8$ Hz, 6H). ^{13}C
 246 **NMR** (151 MHz, CDCl_3) δ 183.8, 157.8, 150.5, 138.1, 125.5, 123.2, 117.9, 111.3,
 247 44.8, 19.3.


248 Analytical data is in accordance with the literature ¹⁴.

249 **1-allylindoline-2,3-dione (2d):**

250  Isolated as orange color solid; 75% yield (140 mg). $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.62-
 251 7.55 (m, 2H), 7.15-7.10 (m, 1H), 6.91 (d, $J = 7.7$ Hz, 1H), 5.92-5.82 (m, 1H), 5.34-5.26
 252 (m, 1H), 4.37-4.32 (m, 2H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 183.80, 158.31, 151.29,
 253 138.68, 130.98, 125.42, 124.06, 118.42, 118.00, 111.32, 42.80.


254 Analytical data is in accordance with the literature ¹⁵.

255 **1-benzylindoline-2,3-dione (2f):**

256  Isolated as orange color solid; 75% yield (140 mg). $^1\text{H NMR}$ (600 MHz, CDCl_3)
 257 δ 7.63-7.59 (m, 1H), 7.50-7.45 (m, 1H), 7.36-7.29 (m, 5H), 7.12-7.07 (m, 1H), 6.78
 258 (d, $J = 8.0$ Hz, 1H), 4.94 (s, 2H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 183.24, 158.28,
 259 150.73, 138.31, 134.50, 129.06, 128.17, 127.43, 125.43, 123.87, 117.69, 111.00,
 260 44.06.

261 Analytical data is in accordance with the literature ¹³.

262 **Synthesis of 2e:**




263

264 A dried round-bottomed flask was charged with IMes·Cl salt (10 mol %) and DBU (10 mol %) in
 265 dry THF (1 mL) under an N_2 atmosphere. To this, the addition of DMSO (0.1 mL),
 266 (vinylsulfonyl)benzene (1.2 mmol), and dropwise addition of N-unsubstituted 2-oxindole (1 mmol)
 267 solution in dry THF (1 mL) at room temperature by using a syringe were carried out. When the reaction
 268 was completed as observed by TLC, the mixture was diluted with water (5 mL) and extracted using

269 EtOAc (15 mL), dried over anhydrous Na₂SO₄, and evaporated under reduced pressure. The crude residue
 270 was purified by column chromatography (5% EtOAc/hexane).

271 **1-(2-(phenylsulfonyl)ethyl)indoline-2,3-dione (2f):**

272 Isolated as orange color solid; 93% yield (292 mg). ¹H NMR (600 MHz, CDCl₃) δ
 273 7.84 (dd, J = 8.3, 1.1 Hz, 2H), 7.67 – 7.61 (m, 2H), 7.55 (dd, J = 7.4, 0.6 Hz, 1H),
 274 7.51 (t, J = 7.9 Hz, 2H), 7.15 (t, J = 7.5 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 4.15 (t, J
 275 = 6.8 Hz, 2H), 3.58 (t, J = 6.8 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 182.1,
 276 158.0, 149.6, 138.6, 138.5, 134.2, 129.4, 127.7, 125.5, 124.2, 117.5, 110.3, 52.1,
 277 34.4.




278 Analytical data is in accordance with the literature ¹⁶.

279 **General Synthetic procedure for 3a-f:**

280 Substrates **2a-f** were prepared according to the reported procedure from ¹⁷. To a solution of **7** (1.0
 281 mmol, 1.0 equiv.) in THF (3mL) added Zn dust (5.0 mmol, 5.0 equiv.), propargyl bromide (3.0 mmol, 3.0
 282 equiv.) at 0°C. Added saturated NH₄Cl (37.0 mmol) dropwise and stirred the reaction mixture for 20
 283 minutes. The reaction was quenched with ice pieces and extracted with ethyl acetate (3*20 mL).
 284 Combined organic phase washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated
 285 under reduced pressure. The crude product was purified by flash column chromatography (Hexane: Ethyl
 286 acetate = 9:1 – 1:1).

287 **3-hydroxy-1-methyl-3-(prop-2-yn-1-yl)indolin-2-one (3a)**

288 Isolated as white color solid; 60% yield (120 mg). ¹H NMR (600 MHz, CDCl₃) δ 7.55
 289 (d, J = 7.2 Hz, 1 H), 7.34 (t, J = 7.6 Hz, 1 H), 7.11 (t, J = 7.5 Hz, 1 H), 6.83 (d, J = 7.8
 290 Hz, 1 H), 3.92 (s, 1 H), 2.90 (dd, J = 16.3, 2.1 Hz, 1 H), 2.72 (dd, J = 16.3, 2.1 Hz, 1 H),
 291 1.97 (t, J = 21.7 Hz, 1 H). ¹³C NMR (151 MHz, CDCl₃) δ 177.02, 143.42, 130.17,
 292 129.26, 124.26, 123.43, 108.57, 77.79, 74.64, 71.4, 28.83, 26.38.




293 **HRMS:** (EI⁺ mode): Calculated for C₁₂H₁₁NO₂: 201.0790, found: 201.0790.

294 Analytical data is in accordance with the literature ¹⁸.

295 **1-ethyl-3-hydroxy-3-(prop-2-yn-1-yl)indolin-2-one (3b)**


296 Isolated as white color solid; 80% yield (172 mg). ¹H NMR (600 MHz, CDCl₃) δ 7.57
 297 (dd, J = 7.4, 0.7 Hz, 1H), 7.36 (td, J = 7.8, 1.2 Hz, 1H), 7.12 (td, J = 7.6, 0.9 Hz, 1H),
 298 6.88 (d, J = 7.8 Hz, 1H), 3.86 – 3.64 (m, 2H), 3.20 (s, 1H), 2.91 (dd, J = 16.5, 2.7 Hz,



299 1H), 2.74 (dd, $J = 16.5, 2.7$ Hz, 1H), 1.97 (t, $J = 2.7$ Hz, 1H), 1.28 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (151
 300 MHz, CDCl_3) δ 176.16, 142.51, 130.11, 129.18, 124.29, 123.08, 108.63, 77.60, 74.31, 71.44, 34.89, 30.95,
 301 28.90, 12.56.


302 HRMS: (EI^+ mode): Calculated for $\text{C}_{13}\text{H}_{13}\text{NO}_2$: 215.0946, found: 215.0946.

303 **3-hydroxy-1-isopropyl-3-(prop-2-yn-1-yl)indolin-2-one (3c)**

304  Isolated as white color solid; 75% yield (171 mg). ^1H NMR (600 MHz, CDCl_3) δ 7.56
 305 (dd, $J = 7.4, 0.9$ Hz, 1H), 7.34 (td, $J = 7.8, 1.3$ Hz, 1H), 7.11 (td, $J = 7.6, 0.8$ Hz, 1H),
 306 7.01 (d, $J = 7.9$ Hz, 1H), 4.58 (dt, $J = 14.1, 7.0$ Hz, 1H), 2.99 (s, 1H), 2.88 (dd, $J = 16.4,$
 307 2.7 Hz, 1H), 2.74 (dd, $J = 16.4, 2.7$ Hz, 1H), 1.95 (s, 1H), 1.49 (dd, $J = 7.0, 4.9$ Hz, 5H).
 308 ^{13}C NMR (151 MHz, CDCl_3) δ 176.68, 142.14, 129.77, 129.61, 124.31, 122.79, 110.12,
 309 77.78, 74.41, 71.07, 44.29, 29.03, 19.46, 19.19.


310 HRMS: (EI^+ mode): Calculated for $\text{C}_{14}\text{H}_{15}\text{NO}_2$: 229.1103, found: 229.1101.

311 **1-allyl-3-hydroxy-3-(prop-2-yn-1-yl)indolin-2-one (3d):**

312  Isolated as white color solid; 85% yield (170 mg). ^1H NMR (400 MHz, CDCl_3) δ 7.56
 313 (d, $J = 7.4$ Hz, 1H), 7.33 (td, $J = 7.8, 1.1$ Hz, 1H), 7.12 (t, $J = 7.5$ Hz, 1H), 6.85 (d, $J =$
 314 7.8 Hz, 1H), 5.83 (ddd, $J = 22.3, 10.4, 5.2$ Hz, 1H), 5.25 (ddd, $J = 13.8, 11.3, 0.9$ Hz,
 315 2H), 4.44 (ddd, $J = 16.4, 3.3, 1.7$ Hz, 1H), 4.22 (dd, $J = 16.4, 5.4$ Hz, 1H), 3.37 (s, 1H),
 316 2.94 (dd, $J = 16.4, 2.6$ Hz, 1H), 2.78 (dd, $J = 16.4, 2.6$ Hz, 1H). ^{13}C NMR (151 MHz,
 317 CDCl_3) δ 176.80, 142.70, 130.98, 130.08, 129.21, 124.26, 123.40, 117.93, 109.54,
 318 77.81, 74.70, 71.50, 42.59, 28.87.

319 Analytical data is in accordance with the literature ¹⁸.


320 **3-hydroxy-1-(2-(phenylsulfonyl)ethyl)-3-(prop-2-yn-1-yl)indolin-2-one (3e)**

321  Isolated as white color solid; 55% yield (195 mg). ^1H NMR (600 MHz, CDCl_3) δ
 322 7.95 – 7.88 (m, 2H), 7.68 (dd, $J = 10.6, 4.3$ Hz, 1H), 7.60 – 7.55 (m, 2H), 7.53 (dd,
 323 $J = 7.4, 0.8$ Hz, 1H), 7.37 (td, $J = 7.8, 1.2$ Hz, 1H), 7.14 (td, $J = 7.7, 0.8$ Hz, 1H),
 324 6.90 (d, $J = 7.8$ Hz, 1H), 4.12 – 4.04 (m, 2H), 3.53 – 3.43 (m, 2H), 3.30 (s, 1H),
 325 2.81 (dd, $J = 16.5, 2.6$ Hz, 1H), 2.65 (dd, $J = 16.5, 2.7$ Hz, 1H), 1.95 (t, $J = 2.6$ Hz,
 326 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 176.55, 141.33, 138.57, 134.25, 130.34,
 327 129.55, 129.01, 128.03, 124.51, 123.75, 108.60, 77.41, 74.10, 71.63, 52.25, 34.11,
 328 28.57.

329 **HRMS:** (EI⁺ mode): Calculated for C₁₉H₁₇NO₄S: 355.0878, found: 355.0878.


330 **1-benzyl-3-hydroxy-3-(prop-2-yn-1-yl)indolin-2-one (3f)**

331 Isolated as white color solid; 75% yield (277 mg). ¹H NMR (600 MHz, CDCl₃) δ
 332 7.58 – 7.51 (m, 1H), 7.37 – 7.17 (m, 6H), 7.10 – 7.03 (m, 1H), 6.70 (d, *J* = 7.9 Hz,
 333 1H), 5.03 (d, *J* = 15.7 Hz, 1H), 4.70 (d, *J* = 15.7 Hz, 1H), 4.33 (s, 1H), 2.93 (ddd, *J*
 334 = 68.8, 16.3, 2.6 Hz, 2H), 1.88 (t, *J* = 2.6 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ
 335 177.33, 142.57, 135.25, 129.98, 129.26, 128.76, 127.76, 127.43, 124.21, 123.41,
 336 109.60, 77.83, 74.86, 71.45, 44.01, 28.74.



337 Analytical data is in accordance with the literature ¹⁷.

338 **General synthetic procedure for homopropargyl alcohols (5c)**




339

340 To a solution of 2-methoxybenzaldehyde (61.1 mg, 53 μL, 0.5 mmol) in methanol (0.5 mL) was
 341 added pinacolallenylboronate (83.1 mg, 90 μL, 0.5 mmol, 1 equiv) and the mixture was stirred at room
 342 temperature for 12 h and then evaporated. The crude product was purified by column chromatography on
 343 silica gel eluting with 15:85 EtOAc/Hexane to afford the title compound **5c** as a pale pink oil (64.4 mg,
 344 79%).

345 ¹H NMR (600 MHz, CDCl₃) δ 7.73 (s, 1H), 7.19 (td, *J* = 7.8, 1.7 Hz, 1H), 7.03 (dd, *J* = 7.6, 1.7 Hz, 1H),
 346 6.93 – 6.80 (m, 2H), 5.02 (ddd, *J* = 9.3, 4.4, 2.1 Hz, 1H), 3.17 (s, 1H), 2.81 (ddd, *J* = 16.9, 9.0, 2.7 Hz, 1H),
 347 2.68 (ddd, *J* = 16.9, 4.5, 2.6 Hz, 1H), 2.14 (t, *J* = 2.6 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 155.51,
 348 129.63, 127.30, 125.42, 120.21, 117.64, 80.43, 73.82, 71.80, 28.21.


349 Analytical data is in accordance with the literature ¹⁹.

350

351 **3.1. General Procedure for the synthesis of spiro-2,5-dihydrofuran products (9a-l):**

352

353 To a solution of PhI(OAc)(NTs₂) **1a** (0.076 g, 0.13 mmol) in DCE (1.0 mL) was added the
 354 corresponding alkyne **8a-l** (0.10 mmol) and the reaction mixture was stirred at 80°C. The reaction mixture
 355 was stirred until the full consumption of the starting material (TLC analysis). The solution was quenched
 356 by addition of ice cold water (5mL) and extracted with DCM (3*10 mL). Combined extracts washed with
 357 brine (1*10 mL), dried over Na₂SO₄ and concentrated under reduced pressure. Residue was purified by
 358 column chromatography (Hexane: EtOAc = 8:2).


359 **4-methyl-N-(5-phenyl-2,5-dihydrofuran-3-yl)-N-tosylbenzenesulfonamide (9a):**

360

361 Synthesized according to the general procedure described above. Isolated as white color solid; 70% yield
 362 (32.8 mg)

363 **M.P:** 110-112°C

364 ¹H NMR (600 MHz, CDCl₃) δ 7.86 (d, *J* = 8.4 Hz, 4H), 7.39 – 7.36 (m, 2H), 7.35 – 7.32 (m, 1H), 7.30 (d,
 365 *J* = 8.2 Hz, 6H), 5.82 (ddd, *J* = 5.8, 3.9, 1.6 Hz, 1H), 5.76 (dd, *J* = 3.9, 2.0 Hz, 1H), 4.68 (ddd, *J* = 11.6,
 366 6.0, 2.1 Hz, 1H), 4.61 (ddd, *J* = 11.6, 3.9, 2.3 Hz, 1H), 2.44 (s, 6H). ¹³C NMR (151 MHz, CDCl₃) δ
 367 145.51, 140.25, 136.01, 134.06, 132.62, 129.77, 128.70, 128.53, 128.50, 126.77, 86.82, 73.74, 21.75.

368 **HRMS:** (EI⁺ mode): Calculated for C₂₄H₂₃NO₅S₂: 469.1018, found: 469.1016.369 **4-methyl-N-(5-methyl-5-phenyl-2,5-dihydrofuran-3-yl)-N-tosylbenzenesulfonamide (9b):**

370


371 Synthesized according to the general procedure described above. Isolated as white color solid; 93% yield
 372 (44.7 mg)

373 **M.P:** 115-117°C

374 **¹H NMR (600 MHz, CDCl₃)** δ 7.77 (d, *J* = 8.4 Hz, 4H), 7.36 (d, *J* = 7.2 Hz, 2H), 7.34 – 7.29 (m, 3H),
 375 7.27 (t, *J* = 4.0 Hz, 5H), 5.87 (t, *J* = 2.1 Hz, 1H), 4.64 (dd, *J* = 11.8, 2.1 Hz, 1H), 4.51 (dd, *J* = 11.7, 2.2
 376 Hz, 1H), 2.45 (s, 6H), 1.67 (s, 3H). **¹³C NMR (151 MHz, CDCl₃)** δ 145.39, 144.35, 138.22, 135.83,
 377 130.80, 129.67, 128.54, 128.41, 127.43, 124.93, 89.80, 72.90, 27.04, 21.75.

378 **HRMS:** (EI⁺ mode): Calculated for C₂₅H₂₅NO₅S₂: 483.1174, found: 483.1178.

379 **N-(5,5-diphenyl-2,5-dihydrofuran-3-yl)-4-methyl-N-tosylbenzenesulfonamide (9c):**




381 Synthesized according to the general procedure described above. Isolated as white color solid; 90% yield
 382 (49.5 mg)

383 **M.P:** 140-142°C

384 **¹H NMR (600 MHz, CDCl₃)** δ 7.71 (d, *J* = 8.3 Hz, 4H), 7.36 (t, *J* = 7.4 Hz, 4H), 7.32 (d, *J* = 7.1 Hz, 2H),
 385 7.27 (d, *J* = 5.6 Hz, 4H), 7.21 (d, *J* = 8.1 Hz, 4H), 6.11 (t, *J* = 1.9 Hz, 1H), 4.66 (d, *J* = 1.9 Hz, 2H), 2.43
 386 (s, 6H). **¹³C NMR (151 MHz, CDCl₃)** δ 145.37, 143.35, 137.09, 135.62, 131.64, 129.74, 129.66, 128.53,
 387 128.32, 127.74, 126.67, 93.86, 73.16, 21.73.

388 **HRMS:** (EI⁺ mode): Calculated for C₃₀H₂₇NO₅S₂: 545.1331, found: 545.1330.

389 **N-(3',4'-dihydro-2'H,5H-spiro[furan-2,1'-naphthalen]-4-yl)-4-methyl-N-**
 390 **tosylbenzenesulfonamide (9d):**




392 Synthesized according to the general procedure described above. Isolated as pale yellow solid, 90% Yield
 393 (45.8 mg)

394 **M.P:** 90-92°C

395 ¹H NMR (600 MHz, CDCl₃) δ = 7.91 (d, *J* = 8.4 Hz, 4H), 7.40 (dd, *J* = 7.7, 1.3 Hz, 1H), 7.35 – 7.32 (m,
396 4H), 7.22 (dd, *J* = 7.6, 1.3 Hz, 1H), 7.19 (dt, *J* = 7.3, 3.7 Hz, 1H), 7.10 – 7.06 (m, 1H), 5.67 (t, *J* = 2.1 Hz,
397 1H), 4.71 (dd, *J* = 11.8, 2.1 Hz, 1H), 4.55 (dd, *J* = 11.8, 2.3 Hz, 1H), 2.82 (dt, *J* = 16.8, 5.1 Hz, 1H), 2.73
398 – 2.64 (m, 1H), 2.45 (s, 6H), 2.10 (ddd, *J* = 12.8, 7.0, 2.3 Hz, 1H), 2.02 – 1.94 (m, 1H), 1.83 (ddd, *J* =
399 13.3, 10.7, 2.8 Hz, 1H), 1.79 – 1.74 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ = 145.48, 138.33, 137.53,
400 136.89, 136.12, 131.91, 129.75, 128.96, 128.56, 128.09, 126.49, 88.19, 72.59, 35.11, 29.70, 29.40, 21.74,
401 19.60.

402 **HRMS:** (EI⁺ mode): Calculated for C₂₇H₂₇NO₅S₂: 509.1331, found: 509.1331.

403 **4-methyl-N-(1-oxaspiro[4.5]dec-3-en-3-yl)-N-tosylbenzenesulfonamide (9e):**




405 Synthesized according to the general procedure described above. Isolated as colorless liquid; 75% yield
406 (34.5 mg)

407 ¹H NMR (600 MHz, CDCl₃) δ 7.87 (d, *J* = 8.4 Hz, 4H), 7.35 (d, *J* = 8.0 Hz, 4H), 5.75 (t, *J* = 1.9 Hz, 1H),
408 4.46 (d, *J* = 2.1 Hz, 2H), 2.47 (s, 6H), 1.69 – 1.62 (m, 4H), 1.60 – 1.56 (m, 2H), 1.40 – 1.32 (m, 4H). ¹³C
409 NMR (151 MHz, CDCl₃) δ 145.38, 138.12, 136.10, 131.09, 129.67, 128.57, 88.91, 71.95, 36.32, 29.71,
410 25.15, 22.97, 21.76.

411 **HRMS:** (EI⁺ mode): Calculated for C₂₃H₂₇NO₅S₂: 461.1331, found: 461.1326.

412 **4-methyl-N-(1-oxaspiro[4.5]deca-3,6-dien-3-yl)-N-tosylbenzenesulfonamide (9f):**



414 Synthesized according to the general procedure described above. Isolated as white color solid; 93% yield
415 (42.6 mg)


416 **M.P:** 95-97°C

417 ¹H NMR (600 MHz, CDCl₃) δ 7.88 (d, *J* = 8.3 Hz, 4H), 7.36 (d, *J* = 8.1 Hz, 4H), 5.89 (dt, *J* = 9.9, 3.7 Hz,
418 1H), 5.64 (t, *J* = 2.1 Hz, 1H), 5.58 (d, *J* = 10.0 Hz, 1H), 4.45 (ddd, *J* = 25.8, 11.6, 2.1 Hz, 2H), 2.47 (s,

419 6H), 1.96 – 1.85 (m, 2H), 1.83 – 1.57 (m, 4H). ¹³C NMR (151 MHz, CDCl₃) δ 145.44, 137.62, 136.09,
420 131.77, 131.41, 129.71, 128.55, 128.17, 86.02, 72.06, 33.94, 24.63, 21.76, 19.40.

421 HRMS: (EI⁺ mode): Calculated for C₂₃H₂₅NO₅S₂: 459.1174, found: 459.1176.

422 **4-methyl-N-(5'H-spiro[chroman-4,2'-furan]-4'-yl)-N-tosylbenzenesulfonamide (9g):**




424 Synthesized according to the general procedure described above. Isolated as white color solid, 80% yield
425 (40.8 mg)

426 M.P: 120-122°C

427 ¹H NMR (600 MHz, CDCl₃) δ = 7.94 (d, *J* = 8.3 Hz, 4H), 7.36 (d, *J* = 8.2 Hz, 4H), 7.32 (dd, *J* = 7.8, 1.4
428 Hz, 1H), 7.23 – 7.19 (m, 1H), 6.95 (t, *J* = 7.1 Hz, 1H), 6.84 (d, *J* = 8.2 Hz, 1H), 5.63 (t, *J* = 1.9 Hz, 1H),
429 4.72 (dd, *J* = 12.0, 1.9 Hz, 1H), 4.57 (dd, *J* = 12.0, 2.1 Hz, 1H), 4.27 (dd, *J* = 7.9, 2.9 Hz, 2H), 2.47 (s, 6H),
430 2.13 (dd, *J* = 10.1, 7.0 Hz, 1H), 2.08 (d, *J* = 7.6 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ = 154.99,
431 130.84, 129.95, 120.62, 119.95, 117.09, 80.12, 74.67, 68.45, 61.96, 54.95, 27.54.

432 HRMS: (EI⁺ mode): Calculated for C₂₆H₂₅NO₆S₂: 511.1123, found: 511.1121.

433 **N-(2',3'-dihydro-5H-spiro[furan-2,1'-inden]-4-yl)-4-methyl-N-tosylbenzenesulfonamide (9h):**




435 Synthesized according to the general procedure described above. Isolated as white color solid; 95% yield
436 (47.0 mg)

437 M.P: 115-117°C

438 ¹H NMR (600 MHz, CDCl₃) δ 7.93 (d, *J* = 8.4 Hz, 4H), 7.35 (d, *J* = 8.0 Hz, 5H), 7.29 (dd, *J* = 6.9, 1.8 Hz,
439 2H), 7.25 – 7.23 (m, 1H), 5.71 (t, *J* = 2.1 Hz, 1H), 4.67 (d, *J* = 2.1 Hz, 1H), 4.54 (d, *J* = 2.2 Hz, 1H), 3.10
440 (dd, *J* = 15.6, 7.5 Hz, 1H), 2.86 – 2.80 (m, 1H), 2.46 (s, 6H), 2.37 (ddd, *J* = 13.7, 8.3, 4.5 Hz, 1H), 2.25
441 (ddd, *J* = 13.8, 8.6, 6.6 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 145.50, 143.78, 143.00, 136.13, 135.93,
442 132.36, 129.77, 129.10, 128.58, 127.12, 124.99, 124.30, 98.08, 76.50, 72.83, 37.81, 29.72, 21.75.

443 **HRMS:** (EI⁺ mode): Calculated for C₂₆H₂₅NO₅S₂: 495.1174, found: 495.1172.

444 **4-methyl-N-tosyl-N-(6'-(trifluoromethyl)-2',3'-dihydro-3H-spiro[furan-2,1'-inden]-4-yl)benzenesulfonamide (9i) :**




446

447 Synthesized according to the general procedure described above. Isolated as pale yellow oil; 60% yield
448 (33.7 mg)

449 ¹H NMR (600 MHz, CDCl₃) δ 7.93 (d, *J* = 8.4 Hz, 4H), 7.54 (d, *J* = 7.9 Hz, 1H), 7.50 (s, 1H), 7.36 (d, *J*
450 = 8.1 Hz, 4H), 7.34 (s, 1H), 5.71 (t, *J* = 2.1 Hz, 1H), 4.63 (d, *J* = 2.1 Hz, 1H), 4.61 (d, *J* = 2.2 Hz, 1H),
451 3.16 – 3.12 (m, 1H), 2.90 – 2.86 (m, 1H), 2.46 (s, 6H), 2.38 – 2.34 (m, 1H), 2.25 – 2.21 (m, 1H). ¹³C
452 NMR (151 MHz, CDCl₃) δ 145.64, 144.72, 135.97, 135.14, 133.01, 129.82 (q, *J* = 32.0 Hz), 128.53,
453 125.46 (q, *J* = 3.8 Hz), 97.46, 72.99, 37.89, 29.71, 21.75.

454 **HRMS:** (EI⁺ mode): Calculated for C₂₇H₂₄F₃NO₅S₂: 563.1048, found: 563.1046.

455 **N-(5-(benzo[d][1,3]dioxol-5-yl)-2,5-dihydrofuran-3-yl)-4-methyl-N-**
456 **tosylbenzenesulfonamide (9j):**



457


458 Synthesized according to the general procedure described above. Isolated as white color solid; 75% yield
459 (35.4 mg)

460 M.P: 92-94°C

461 ¹H NMR (600 MHz, CDCl₃) δ 7.89 (d, *J* = 8.4 Hz, 4H), 7.34 (d, *J* = 8.1 Hz, 4H), 6.82 – 6.75 (m, 3H),
462 5.97 (dd, *J* = 5.1, 1.3 Hz, 2H), 5.75 – 5.74 (m, 1H), 4.66 – 4.55 (m, 2H), 2.46 (s, 6H). ¹³C NMR (151
463 MHz, CDCl₃) δ 148.04, 147.80, 145.54, 136.06, 134.18, 133.86, 132.85, 129.81, 128.52, 120.56, 108.23,
464 107.40, 101.18, 86.63, 73.51, 21.76.

465 **HRMS:** (EI⁺ mode): Calculated for C₂₅H₂₃NO₇S₂: 513.0916, found: 513.0916

466 **N-(5-isopentyl-5-methyl-2,5-dihydrofuran-3-yl)-4-methyl-N-tosylbenzenesulfonamide (9k):**



467


468 Synthesized according to the general procedure described above. Isolated as white color solid; 93% yield
469 (44.3 mg)

470 **M.P:** 90-92°C

471 **¹H NMR (600 MHz, CDCl₃)** δ 7.88 (d, *J* = 8.4 Hz, 4H), 7.35 (d, *J* = 8.0 Hz, 4H), 5.62 (t, *J* = 2.1 Hz, 1H),
472 4.44 (ddd, *J* = 26.1, 11.7, 2.2 Hz, 2H), 2.47 (s, 6H), 1.62 – 1.58 (m, 1H), 1.54 – 1.48 (m, 2H), 1.28 (s, 3H),
473 1.24 – 1.19 (m, 2H), 0.89 (t, *J* = 6.4 Hz, 6H). **¹³C NMR (151 MHz, CDCl₃)** δ 145.36, 138.55, 136.21,
474 130.79, 129.71, 128.50, 89.76, 72.84, 38.66, 33.27, 29.71, 28.34, 25.93, 22.67, 22.58, 21.75.

475 **HRMS:**(EI⁺ mode): Calculated for C₂₄H₃₁NO₅S₂: 477.1644, found: 477.1644

476 **N-(5-hexyl-5-methyl-2,5-dihydrofuran-3-yl)-4-methyl-N-tosylbenzenesulfonamide (91):**



477


478 Synthesized according to the general procedure described above. Isolated as white color solid; 89% yield
479 (43.6 mg)

480 **M.P:** 95-97°C

481 **¹H NMR (600 MHz, CDCl₃)** δ 7.88 (d, *J* = 8.4 Hz, 4H), 7.34 (d, *J* = 8.0 Hz, 4H), 5.62 (t, *J* = 2.1 Hz, 1H),
482 4.44 (dd, *J* = 4.3, 2.2 Hz, 2H), 2.47 (s, 6H), 1.60 (s, 6H), 0.88 (q, *J* = 7.0 Hz, 10H). **¹³C NMR (151 MHz,**
483 **CDCl₃)** δ 145.36, 138.53, 136.21, 130.79, 129.70, 128.51, 89.73, 72.84, 40.85, 31.89, 29.63, 25.92, 24.31,
484 22.63, 21.75, 14.13.


485 **HRMS:** (EI⁺ mode): Calculated for C₂₅H₃₃NO₅S₂: 495.1800, found: 495.1802

486

487 **3.2. General Procedure for the synthesis of 2,3-dihydrofuran products:**

488

489 To a solution of $\text{PhI}(\text{OAc})(\text{NTs}_2)$ **1a** (0.076 g, 0.13 mmol) in DCE (1.0 mL) was added the
 490 corresponding alkyne (0.10 mmol) and the reaction mixture was stirred at 80°C. The reaction mixture was
 491 stirred until the full consumption of starting material (TLC analysis). The solution was quenched by the
 492 addition of ice-cold water (5mL) and extracted with DCM (3*10 mL). The combined extract was washed
 493 with brine (1*10 mL), dried over Na_2SO_4 and concentrated under reduced pressure. The residue was
 494 purified by column chromatography (Hexane: EtOAc = 9:1).


495 **N-(4,5-dihydrofuran-3-yl)-4-methyl-N-tosylbenzenesulfonamide (6a):**

496

497 Synthesized according to the general procedure described above. Isolated as white color solid; 85% yield
 498 (33.4mg)

499 **M.P:** 110-112°C

500 ¹H NMR (400 MHz, CDCl_3) δ 7.88 (d, $J = 8.4$ Hz, 4H), 7.34 (d, $J = 8.3$ Hz, 4H), 6.22 (t, $J = 1.9$ Hz, 1H),
 501 4.48 (t, $J = 9.8$ Hz, 2H), 2.65 (td, $J = 9.9, 1.9$ Hz, 2H), 2.45 (s, 6H). ¹³C NMR (101 MHz, CDCl_3) δ
 502 150.32, 145.02, 136.44, 129.61, 128.31, 111.33, 71.50, 30.20, 21.66.

503 **HRMS:** (EI^+ mode): Calculated for $\text{C}_{18}\text{H}_{19}\text{NO}_5\text{S}_2$: 393.0705, found: 393.0709.504 **4-methyl-N-(5-methyl-4,5-dihydrofuran-3-yl)-N-tosylbenzenesulfonamide (6b):**

505


506 Synthesized according to the general procedure described above. Isolated as white color solid; 93% yield
 507 (37.8 mg)

508 **M.P:** 120-122°C

509 $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.88 (d, $J = 8.3$ Hz, 4H), 7.34 (d, $J = 8.2$ Hz, 4H), 6.21 – 6.11 (m, 1H),
 510 4.82 (ddd, $J = 10.1, 6.9, 3.8$ Hz, 1H), 2.78 (ddd, $J = 13.5, 10.1, 2.0$ Hz, 1H), 2.46 (s, 6H), 2.22 (ddd, $J =$
 511 13.6, 7.2, 1.8 Hz, 1H), 1.35 (d, $J = 6.3$ Hz, 3H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 149.68, 145.05, 136.51,
 512 129.65, 129.62, 128.43, 128.36, 110.08, 80.16, 37.26, 22.05, 21.72.

513 **HRMS:** (EI^+ mode): Calculated for $\text{C}_{19}\text{H}_{21}\text{NO}_5\text{S}_2$: 407.0861, found: 407.0860.

514 **N-(5-(2-methoxyphenyl)-4,5-dihydrofuran-3-yl)-4-methyl-N-tosylbenzenesulfonamide (6c):**




516 Synthesized according to the general procedure described above (**Reaction was completed in room**
 517 **temperature**). Isolated as white color solid; 75% yield (37.4mg)

518 **M.P:** 92-94°C

519 $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.85 (d, $J = 8.3$ Hz, 4H), 7.38 (dd, $J = 7.6, 1.4$ Hz, 1H), 7.32 (dd, $J = 7.8,$
 520 1.3 Hz, 1H), 7.29 (t, $J = 6.3$ Hz, 4H), 7.03 (td, $J = 7.5, 0.6$ Hz, 1H), 6.89 (d, $J = 8.2$ Hz, 1H), 6.39 (s, 1H),
 521 5.97 (dd, $J = 11.0, 8.2$ Hz, 1H), 3.82 (s, 3H), 3.16 (ddd, $J = 13.9, 11.1, 2.0$ Hz, 1H), 2.44 (s, 6H), 2.40 (dd,
 522 $J = 8.2, 1.9$ Hz, 1H). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 155.95, 149.86, 144.97, 136.43, 129.61, 129.58,
 523 129.11, 128.38, 126.02, 120.69, 110.48, 110.38, 79.80, 55.37, 37.44, 21.71.

524 **HRMS:** (EI^+ mode): Calculated for $\text{C}_{25}\text{H}_{25}\text{NO}_6\text{S}_2$: 499.1123, found: 499.1121.

525 **N-(4,5-dihydrofuran-3-yl)-4-methyl-N-(methylsulfonyl)benzenesulfonamide (6ab):**




527 Synthesized according to the general procedure described above. Isolated as white color solid; 50% yield
 528 (15.8 mg).

529 **M.P:** 104-106°C

530 $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.91 (d, $J = 8.3$ Hz, 2H), 7.34 (d, $J = 8.3$ Hz, 2H), 6.30 (t, $J = 1.9$ Hz, 1H),
 531 4.52 (t, $J = 9.8$ Hz, 2H), 3.45 (s, 3H), 2.72 (td, $J = 10.0, 1.8$ Hz, 2H), 2.46 (s, 3H). $^{13}\text{C NMR}$ (151 MHz,
 532 CDCl_3) δ 150.09, 145.47, 143.29, 142.81, 135.32, 129.72, 128.58, 110.87, 71.52, 44.13, 30.35, 21.73.

533


534

535 **3.3. General Procedure for the synthesis of 4a-f:**

536

537 To a solution of PhI(OAc)(NTs₂) **1a** (0.076 g, 0.13 mmol) in DCE (1.0 mL) was added the
 538 corresponding alkyne **3a-f** (0.10 mmol) and the reaction mixture was stirred at 80°C. The reaction mixture
 539 was stirred until the full consumption of starting material (TLC analysis). The solution was quenched by
 540 addition of ice cold water (5mL) and extracted with DCM (3*10 mL). Combined extracts washed with
 541 brine (1*10 mL), dried over Na₂SO₄ and concentrated under reduced pressure. Residue was purified by
 542 column chromatography (Hexanes: Ethyl acetate = 9:1 – 6:4).

543 **4-methyl-N-(1'-methyl-2'-oxo-3H-spiro[furan-2,3'-indolin]-4-yl)-N-**
 544 **tosylbenzenesulfonamide (4a):**



545

546 Synthesized according to the general procedure described above. Isolated as white color solid; 84%
 547 yield (44 mg)


548 **M.P:** 180-182°C

549 **¹H NMR (600 MHz, CDCl₃)** δ 8.04 – 7.89 (m, 4H), 7.56 (d, *J* = 7.3 Hz, 2H), 7.36 (d, *J* = 7.8 Hz,
 550 4H), 7.13 (t, *J* = 7.4 Hz, 1H), 6.82 (d, *J* = 7.7 Hz, 1H), 6.41 (d, *J* = 1.7 Hz, 1H), 3.20 (s, 3H), 3.14
 551 (d, *J* = 14.3 Hz, 1H), 2.90 (d, *J* = 14.3 Hz, 1H), 2.46 (s, 6H). **¹³C NMR (151 MHz, CDCl₃)** δ
 552 173.59, 148.93, 145.25, 143.34, 130.89, 129.78, 128.52, 124.31, 123.79, 110.35, 108.49, 85.39,
 553 38.81, 29.71, 26.39, 21.75.

554 **HRMS:** (EI⁺ mode): Calculated for C₂₆H₂₄N₂O₆S₂: 524.1076, found: 524.1076.

555 **N-(1'-ethyl-2'-oxo-3H-spiro[furan-2,3'-indolin]-4-yl)-4-methyl-N-tosylbenzenesulfonamide**

556 **(4b):**



557

558 Synthesized according to the general procedure described above. Isolated as white color solid; 85% yield

559 (45 mg)

560 **M.P:** 176-178°C

561 **¹H NMR (600 MHz, CDCl₃)** δ 7.96 (d, *J* = 8.0 Hz, 4H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.56 (d, *J* = 7.2 Hz, 1H),

562 7.36 (d, *J* = 8.2 Hz, 4H), 7.12 (t, *J* = 7.4 Hz, 1H), 6.84 (d, *J* = 7.8 Hz, 1H), 6.40 (s, 1H), 3.74 (td, *J* = 14.1,

563 7.1 Hz, 2H), 3.14 (d, *J* = 14.3 Hz, 1H), 2.90 (d, *J* = 14.3 Hz, 1H), 2.46 (s, 6H), 1.35 – 1.30 (m, 3H). **¹³C**


564 **NMR (151 MHz, CDCl₃)** δ 173.25, 148.95, 145.25, 130.84, 129.78, 129.62, 128.73, 128.52, 124.51,

565 123.59, 110.31, 108.63, 85.40, 38.81, 34.99, 29.71, 21.75, 12.54.

566 **HRMS: (EI⁺ mode):** Calculated for C₂₇H₂₆N₂O₆S₂: 538.1232, found: 538.1234.

567 **N-(1'-isopropyl-2'-oxo-3H-spiro[furan-2,3'-indolin]-4-yl)-4-methyl-N-**

568 **tosylbenzenesulfonamide (4c):**



569

570 Synthesized according to the general procedure described above. Isolated as white color solid; 90% yield

571 (49 mg)

572 **M.P:** 175-177°C

573 **¹H NMR (600 MHz, CDCl₃)** δ 7.96 (d, *J* = 8.4 Hz, 4H), 7.56 (dd, *J* = 7.4, 0.9 Hz, 1H), 7.36 (d, *J* = 8.0 Hz,

574 4H), 7.33 (d, *J* = 1.3 Hz, 1H), 7.10 (d, *J* = 0.6 Hz, 1H), 6.97 (d, *J* = 8.0 Hz, 1H), 6.38 (t, *J* = 2.0 Hz, 1H),


575 4.56 – 4.53 (m, 1H), 3.16 (dd, *J* = 14.3, 2.3 Hz, 1H), 2.88 (dd, *J* = 14.3, 1.8 Hz, 1H), 2.46 (s, 6H), 1.49 (dd,

576 *J* = 7.0, 1.2 Hz, 6H). **¹³C NMR (151 MHz, CDCl₃)** δ 171.45, 148.94, 145.21, 142.12, 136.25, 130.61,

577 129.77, 129.61, 128.52, 124.62, 123.24, 110.15, 85.23, 60.56, 44.29, 31.94, 29.71, 22.71, 21.74.

578 **HRMS:** (EI⁺ mode): Calculated for C₂₈H₂₈N₂O₆S₂: 552.1389, found: 552.1391.

579 **N-(1'-allyl-2'-oxo-3H-spiro[furan-2,3'-indolin]-4-yl)-4-methyl-N-tosylbenzenesulfonamide (4d):**



580

581 Synthesized according to the general procedure described above. Isolated as white color solid; 65% yield

582 (35 mg)


583 **M.P:** 166-168°C

584 ¹H NMR (400 MHz, CDCl₃) δ 7.96 (d, *J* = 8.4 Hz, 4H), 7.56 (d, *J* = 7.3 Hz, 1H), 7.36 (d, *J* = 8.2 Hz, 4H), 7.31 (d, *J*
585 = 7.8 Hz, 1H), 7.12 (t, *J* = 7.5 Hz, 1H), 6.81 (d, *J* = 8.0 Hz, 1H), 6.40 (s, 1H), 5.87 – 5.79 (m, 13H), 5.24 (d, *J* = 11.3
586 Hz, 2H), 4.31 (t, *J* = 5.2 Hz, 2H), 3.16 (dd, *J* = 14.4, 2.2 Hz, 1H), 2.95 – 2.89 (m, 1H), 2.46 (s, 6H). ¹³C NMR (151
587 MHz, CDCl₃) δ 173.37, 148.94, 145.26, 142.55, 130.79, 129.79, 128.52, 124.40, 123.76, 118.05, 109.40,
588 85.33, 42.52, 29.71, 21.75.

589 **HRMS:** (EI⁺ mode): Calculated for C₂₈H₂₆N₂O₆S₂: 550.1232, found: 550.1232.

590 **4-methyl-N-(2'-oxo-1'-(2-(phenylsulfonyl)ethyl)-3H-spiro[furan-2,3'-indolin]-4-yl)-N-**

591 **tosylbenzenesulfonamide (4e):**



592

593 Synthesized according to the general procedure described above. Isolated as white color solid; 75% yield


594 (50 mg)

595 **M.P:** 180-182°C

596 $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.96 – 7.91 (m, 4H), 7.91 – 7.89 (m, 2H), 7.65 (dd, $J = 10.6, 4.3$ Hz, 1H),
 597 7.55 (dd, $J = 7.1, 1.1$ Hz, 2H), 7.54 – 7.51 (m, 2H), 7.39 (dd, $J = 7.8, 1.2$ Hz, 1H), 7.36 (dd, $J = 6.9, 4.7$
 598 Hz, 4H), 7.15 (td, $J = 7.7, 0.8$ Hz, 1H), 6.90 (d, $J = 7.9$ Hz, 1H), 6.35 (s, 1H), 3.55 (dt, $J = 14.3, 7.2$ Hz,
 599 2H), 3.50 – 3.42 (m, 2H), 3.00 (dd, $J = 14.5, 2.2$ Hz, 1H), 2.78 (dd, $J = 14.5, 1.9$ Hz, 1H), 2.46 (s, 6H). ^{13}C
 600 NMR (151 MHz, CDCl_3) δ 173.63, 148.75, 145.31, 141.40, 138.68, 136.19, 134.22, 131.06, 129.78,
 601 129.50, 128.49, 127.93, 124.70, 124.26, 110.36, 108.70, 84.94, 52.38, 38.95, 31.60, 22.67, 21.75.

602 HRMS: (EI^+ mode): Calculated for $\text{C}_{33}\text{H}_{30}\text{N}_2\text{O}_3\text{S}_3$: 678.1164, found: 678.1166.

603 N-(1'-benzyl-2'-oxo-3H-spiro[furan-2,3'-indolin]-4-yl)-4-methyl-N-tosylbenzenesulfonamide
 604 (4f):



605


606 Synthesized according to the general procedure described above. Isolated as white color solid; 91% yield
 607 (54 mg)

608 M.P: 180-182°C


609 $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.97 (d, $J = 8.3$ Hz, 4H), 7.56 (d, $J = 6.8$ Hz, 1H), 7.37 (d, $J = 8.1$ Hz, 3H),
 610 7.31 (dt, $J = 20.2, 7.4$ Hz, 4H), 7.26 – 7.22 (m, 1H), 7.09 (t, $J = 7.2$ Hz, 1H), 6.70 (d, $J = 7.9$ Hz, 1H), 6.43
 611 (s, 1H), 4.92 (d, $J = 15.6$ Hz, 1H), 4.85 (d, $J = 15.6$ Hz, 1H), 3.21 (dd, $J = 14.3, 2.2$ Hz, 1H), 2.95 (dd, $J =$
 612 14.3, 1.7 Hz, 1H), 2.47 (s, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 173.80, 148.99, 145.27, 142.45, 136.24,
 613 135.13, 130.80, 129.80, 129.07, 128.91, 128.53, 127.86, 127.29, 124.40, 123.83, 110.33, 109.54, 85.42,
 614 43.94, 38.98, 21.75.

615 HRMS: (EI^+ mode): Calculated for $\text{C}_{32}\text{H}_{28}\text{N}_2\text{O}_6\text{S}_2$: 600.1389, found: 600.1392.



616




617




618











621







622




















635




636









641





642





643





644







645







646

































663







664


































683




684









687





688







689







690



































703 4. MTT Assay result:

Compound No:	Product	Cell Viability %		
		500 μ M	50 μ M	5 μ M
4a		75.42 \pm 19.45	103.81 \pm 20.38	94.84 \pm 8.90
4b		81.10 \pm 17.49	99.76 \pm 12.60	101.66 \pm 3.51
4c		94.64 \pm 2.05	114.38 \pm 6.80	117.16 \pm 2.41
4d		87.19 \pm 4.49	102.80 \pm 3.44	101.71 \pm 3.50
4e		91.08 \pm 1.09	105.79 \pm 0.52	96.82 \pm 7.99
4f		75.42 \pm 0.02	69.93 \pm 12.64	70.59 \pm 11.60
9a		86.57 \pm 0.00	76.54 \pm 5.95	82.05 \pm 0.47
9b		94.73 \pm 6.26	115.59 \pm 13.34	109.27 \pm 10.46

9c		85.73 ± 24.03	101.56 ± 15.13	105.25 ± 1.55
9d		103.04 ± 3.20	82.71 ± 5.55	91.21 ± 5.29
9e		86.84 ± 15.96	91.03 ± 42.48	94.14 ± 44.90
9f		83.30 ± 4.62	80.56 ± 0.27	81.77 ± 0.87
9g		89.30 ± 1.35	82.18 ± 10.64	81.44 ± 6.51
9i		79.14 ± 4.09	76.80 ± 3.40	75.01 ± 2.89
9j		103.40 ± 3.72	81.74 ± 4.17	87.06 ± 0.59
9k		105.24 ± 12.93	122.76 ± 5.06	126.85 ± 11.29
9l		83.20 ± 8.44	106.47 ± 16.62	101.20 ± 0.10
6a		103 ± 3.20	82.71 ± 5.55	91.21 ± 5.29
6b		77.48 ± 2.73	67.77 ± 9.59	68.66 ± 8.86

6c		82.85 ± 9.33	75.32 ± 1.31	77.21 ± 0.22
----	---	--------------	--------------	--------------

704

705 **Material and Method**

706 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay was
 707 performed to evaluate the cell viability according to the method described by Hwang et.al
 708 (Hwang et al, 2016). SH-S5Y5 cells at the density of 1*10⁴cells /wall were seeded in the 96 well-
 709 cultured plates and incubated in a CO₂ incubator for 24 Hours. Seeded cells were pre-treated with
 710 different concentrations of the samples. Treated plates were incubated for 24 hours in the
 711 incubator and a cell viability assay was performed. Treated cell's conditioned medium was used
 712 to evaluate the attached cells were used to evaluate cell viability assay. Cells were incubated for
 713 1h after adding 50 μL MTT solution to each well. After incubation MTT was removed from the
 714 well and dimethyl sulfoxide (DMSO, 100μM/ well) was added and the solution get changed to
 715 purple/formazan colour. The absorbance was measured spectrophotometrically at 570 nM.

716 MTT reagent converts the formazan by mitochondrial dehydrogenase. The survival rate is
 717 increased by using the principle that the amount formed is reduced and the color development is
 718 weakened.

719 It is calculated as follows

720 First calculation OD₅₇₀ of each well721 Second calculation Viability (%) = [OD_{(570) e} / OD_{(570) b}] * 100722 OD_{(570) e} Absorbance of test substance-treated wells723 OD_{(570) b} Absorbance of wells treated with blank test solution

724

725

726 **5. References and Notes**

- 727 1. C. Röben, J. A. Souto, Y. González, A. Lishchynskiy and K. Muñiz, *Angew. Chem. Int. Ed.*, 2011, **50**, 9478-
728 9482.
- 729 2. S. Estopiñá-Durán, L. J. Donnelly, E. B. McLean, B. M. Hockin, A. M. Z. Slawin and J. E. Taylor, *Eur. J. Org.*
730 *Chem.*, 2019, **25**, 3950-3956.
- 731 3. X. Fan, T. Lei, Z. Liu, X. -L. Yang, Y. -Y. Cheng, G. Liang, B. Chen, C. -H. Tung and L. -Z. Wu, *Eur. J. Org.*
732 *Chem.*, 2020, **2020**, 1551-1558.
- 733 4. J. C. Walters, A.F. Tierno, A. H. Dubin and S. E. Wengryniuk, *Eur. J. Org. Chem.*, 2018, **2018**, 1460-1464.
- 734 5. T. Moriai, T. Tsukamoto, M. Tanabe, T. Kambe and K. Yamamoto, *Angew. Chem. Int. Ed.*, 2020, **59**,
735 23051-23055.
- 736 6. Y. Ma, J. Li, J. Ye, D. Liu and W. Zhang, *Chem. Commun.*, 2018, **54**, 13571-13574.
- 737 7. G. Szöllösi and V.J. Kolcsár, *ChemCatChem.*, 2019, **11**, 820-830.
- 738 8. S. S. Chandankar and Raghavan, *Org. Lett.*, 2020, **22**, 653-655.
- 739 9. D. J. Wardrop and J. Fritz, *Org. Lett.*, 2006, **8**, 3659-3662.
- 740 10. N. Iwasawa, S. Watanabe, A. Ario and H. Sogo, *J. Am. Chem. Soc.*, 2018, **140**, 7769-7772.
- 741 11. A. K. Ghosh, R. P. Nyalapatla, S. Kovala, K. V. Rao, M. Brindisi, H. L. Osswald, M. Amano, M. Aoki, J.
742 Agniswamy, Y.-F. Wang, I. T. Weber and H. Mitsuya, *J. Med. Chem.*, 2018, **61**, 4561-4577.
- 743 12. A. A. Moiseeva, O. I. Artyushin, L. V. Anikina and V. K. Brel, *Bioorg. Med. Chem. Lett.*, 2019, **29**,
744 126617.
- 745 13. M. S. Schmidt, A. M. Reverdito, L. Kremenchuzky, I. A. Perillo and M. M. Blanco, *Molecules.*, **2008**, **13**,
746 831-840.
- 747 14. F. Shi, Z. -L. Tao, S. -W. Luo, S. -J. Tu and L. -Z. Gong, *Eur. J. Org. Chem.*, 2012, **18**, 6885-6894.
- 748 15. M. D. Greenhalgh, S. M. Smith, D. M. Walden, J. E. Taylor, Z. Brice, E. R. T. Robinson, C. Fallan, D. B.
749 Cordes, A. M. Z. Slawin, H. C. Richardson, M. A. Grove, P. H.-Y. Cheong and A. D. Smith, *Angew. Chem. Int.*
750 *Ed.*, 2018, **57**, 3200-3206.
- 751 16. C. Mudithanapelli, C. S. Vasam, R. Vadde and M. -h. Kim, *ACS Omega.*, 2018, **3**, 17646-17655.
- 752 17. L. R. Chowhan, M. S. Reddy and N. S. Kumar, *J. Chem. Sci.*, 2017, **129**, 1205-1209.
- 753 18. N. Gupta, R. Tak, M. Nazish, A. Jakhar, N. -u. H. Khan and R. I. Kureshy, *Eur. J. Org. Chem.*, 2018, **2018**,
754 1384-1392.
- 755 19. T. Thaima and S. G. Pyne, *Org. Lett.*, 2015, **17**, 778-781.

756

757